Nebacumab

Nebacumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	endotoxin
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	J06BC01 (WHO) ;
Identifiers
CAS Number	138661-01-5 ;
ChemSpider	none;
UNII	908FWN27WK;
KEGG	D05126 ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.^[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.^[2]

References

^ Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.
^ WHO: Consolidated List of Products

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.

[2] WHO: Consolidated List of Products

[1]

[2]